A Phase 2 interventional study of Enzalutamide in Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 12 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.
Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 51st largest by enrollment, is one of 4 that started in 2011, is one of 65 in phase 2, and was the 8th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
53 studies in Prostatic Neoplasms by Astellas Pharma Inc: 5 open now, 7 under way, 1 of them phase 3. Of 46 finished, 13 (28%) have results posted.
Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, this one is the 20th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2011, is one of 14 in phase 2, and was the 17th registered.
Astellas Pharma Inc’s Prostatic Neoplasms studies by the year they started, since 2001.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Astellas Pharma Inc’s 53 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has previously or is currently receiving:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
Drug: Enzalutamide
Oral
Also known as: Xtandi, MDV3100
Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25
A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 25 for any reason were treated as non-responders.
Time frame: Baseline and Week 25
Number of Participants With Adverse Events
Each adverse event (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs). A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: * Resulted in death * Was life-threatening * Resulted in persistent or significant disability/incapacity * Resulted in congenital anomaly or birth defect * Required inpatient hospitalization or led to prolongation of hospitalization * Other medically important events.
Time frame: From first dose of study drug up to 30 days after last dose of study drug; median duration of treatment of 1666.0 days (range of 52-2052)
Percent Change From Baseline in PSA
Time frame: Baseline and Weeks 25, 49, 97, 169 and Week 265 (End of Study)
Percent Change From Baseline in Sex Hormone-Binding Globulin (SHBG)
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Androstenedione
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Dehydroepiandrosterone (DHEA)
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Dihydrotestosterone (DHT)
Time frame: Baseline and Week 25 and 49
Percent Change From Baseline in Estradiol
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Follicle-Stimulating Hormone (FSH)
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Luteinizing Hormone (LH)
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Prolactin
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Total Testosterone
Time frame: Baseline and Weeks 25 and 49
Percent Change From Baseline in Free Testosterone
Time frame: Baseline and Weeks 25 and 49
Plasma Concentration of Enzalutamide at Pre-dose (Ctrough)
Time frame: Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25
Plasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)
Time frame: Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25
Percentage of Participants With a PSA Response at Weeks 49, 97 and 169
A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 49, week 97 or week 169 for any reason were treated as non-responders.
Time frame: Baseline and Weeks 49, 97 and 169
Percentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level
Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, week 97 or week 169 were considered non-responders.
Time frame: Baseline and Weeks 25, 49, 97 and 169
Percentage of Participants With PSA ≤ 4 ng/ml
Participants with unknown or missing PSA results at week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25. Participants with unknown or missing PSA results at week 49, 97 and 169 were considered non-responders.
Time frame: Weeks 25, 49, 97 and 169
Percentage of Participants With PSA ≤ 0.1 ng/ml
Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, 97 or 169 were considered non-responders.
Time frame: Weeks 25, 49, 97 and 169
Maximum Decline From Baseline in PSA
The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.
Time frame: Baseline to Week 25 and from Baseline up to the EOS date of 27 Apr 2017; median duration of treatment of 1666.0 days (range of 52-2052)
Time to PSA Response
Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.
Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Time to PSA Decline ≥ 90%
Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.
Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Time to PSA ≤ 4 ng/ml
Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.
Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Time to PSA ≤ 0.1 ng/ml
Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded. Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.
Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Time to PSA Progression
Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.
Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
PSA Doubling Time
PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.
Time frame: From Baseline to Week 25
This was a multinational, phase 2, open-label, single-arm, efficacy and safety study of oral enzalutamide in participants with prostate cancer who had noncastrate levels of testosterone at study entry.
| Milestone | Enzalutamide |
|---|---|
| Started | 67 |
| Treatment received | 67 |
| Completed | 27 |
| Not completed | 40 |
| Withdrew: Death | 5 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Other-transitioned to 9785-cl-0123 | 29 |
| Withdrew: Other-miscellaneous reason | 2 |
A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 25 for any reason were treated as non-responders.
| Percentage of Participants | Enzalutamide |
|---|---|
| Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25 | 92.5 (83.44 to 97.53) |
Each adverse event (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs). A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: * Resulted in death * Was life-threatening * Resulted in persistent or significant disability/incapacity * Resulted in congenital anomaly or birth defect * Required inpatient hospitalization or led to prolongation of hospitalization * Other medically important events.
| Participants | Enzalutamide |
|---|---|
| Any Adverse Events | 67 |
| Drug Regimen Related Adverse Events | 65 |
| Deaths | 5 |
| Serious Adverse Events | 24 |
| Drug Regimen Related Serious Adverse Events | 5 |
| AEs Leading to Discontinuation of Study Drug | 14 |
| DRRAEs Leading to Discontinuation of Study Drug | 7 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | -97.82 ± 5.744 |
| Week 49 | -98.96 ± 2.767 |
| Week 97 | -99.44 ± 1.114 |
| Week 169 | -91.74 ± 27.808 |
| Week 265 (End of Study) | -0.70 ± 368.253 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 100.60 ± 49.362 |
| Week 49 | 88.45 ± 41.911 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 51.06 ± 59.367 |
| Week 49 | 49.94 ± 55.449 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 9.59 ± 58.247 |
| Week 49 | 10.54 ± 54.864 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 51.72 ± 57.511 |
| Week 49 | 74.35 ± 101.451 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 71.69 ± 73.150 |
| Week 49 | 81.00 ± 82.811 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 46.99 ± 46.389 |
| Week 49 | 62.18 ± 78.371 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 184.66 ± 120.683 |
| Week 49 | 215.18 ± 163.732 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 16.79 ± 45.497 |
| Week 49 | 9.64 ± 30.003 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 114.29 ± 73.692 |
| Week 49 | 101.73 ± 76.070 |
| Percent Change | Enzalutamide |
|---|---|
| Week 25 | 46.39 ± 59.551 |
| Week 49 | 43.74 ± 55.721 |
| μg/mL | Enzalutamide |
|---|---|
| Week 2 | 7.225 ± 1.8050 |
| Week 3 | 10.559 ± 2.1967 |
| Week 4 | 11.838 ± 2.4605 |
| Week 5 | 12.161 ± 2.8496 |
| Week 9 | 11.606 ± 3.0084 |
| Week 13 | 11.868 ± 2.9760 |
| Week 21 | 11.224 ± 2.8899 |
| Week 25 | 11.668 ± 2.7624 |
| μg/mL | Enzalutamide |
|---|---|
| Week 2 | 2.527 ± 1.0440 |
| Week 3 | 5.344 ± 1.7079 |
| Week 4 | 8.182 ± 2.4366 |
| Week 5 | 9.962 ± 2.7584 |
| Week 9 | 12.128 ± 3.1262 |
| Week 13 | 12.780 ± 3.2564 |
| Week 21 | 11.717 ± 2.9502 |
| Week 25 | 12.146 ± 2.5845 |
A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 49, week 97 or week 169 for any reason were treated as non-responders.
| Percentage of Participants | Enzalutamide |
|---|---|
| Week 49 | 80.6 (69.11 to 89.24) |
| Week 97 | 67.2 (54.60 to 78.15) |
| Week 169 | 56.7 (44.04 to 68.78) |
Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, week 97 or week 169 were considered non-responders.
| Percentage of Participants | Enzalutamide |
|---|---|
| Week 25 | 91.0 |
| Week 49 | 98.1 |
| Week 97 | 100.0 |
| Week 169 | 88.1 |
Participants with unknown or missing PSA results at week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25. Participants with unknown or missing PSA results at week 49, 97 and 169 were considered non-responders.
| Percentage of Participants | Enzalutamide |
|---|---|
| Week 25 | 92.5 |
| Week 49 | 94.4 |
| Week 97 | 100.0 |
| Week 169 | 95.2 |
Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, 97 or 169 were considered non-responders.
| Percentage of Participants | Enzalutamide |
|---|---|
| Week 25 | 44.8 |
| Week 49 | 63.0 |
| Week 97 | 73.3 |
| Week 169 | 61.9 |
The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.
| Percent Change | Enzalutamide |
|---|---|
| Maximum Decline by Week 25 | -98.32 ± 2.880 |
| Maximum Decline by EOS | -99.10 ± 2.659 |
Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.
| Days | Enzalutamide |
|---|---|
| Time to PSA Response | 29 (28 to 31) |
Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.
| Days | Enzalutamide |
|---|---|
| Time to PSA Decline ≥ 90% | 55 (29 to 57) |
Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.
| Days | Enzalutamide |
|---|---|
| Time to PSA ≤ 4 ng/ml | 29 (9 to 57) |
Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded. Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.
| Days | Enzalutamide |
|---|---|
| Time to PSA ≤ 0.1 ng/ml | 168 (58 to 581) |
Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.
| Days | Enzalutamide |
|---|---|
| Time to PSA Progression | NA (NA to NA) |
PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.
No measurements were reported for this outcome.
Collected over From first dose of study drug up to 30 days after last dose of study drug; median duration of treatment of 1666.0 days (range of 52-2052). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide | 5/67 (7.5%) | 24/67 (35.8%) | 66/67 (98.5%) |
| Event | Enzalutamide |
|---|---|
| Atrial fibrillationCardiac disorders | 4/67 |
| Angina pectorisCardiac disorders | 2/67 |
| PneumoniaInfections and infestations | 2/67 |
| SyncopeNervous system disorders | 2/67 |
| Urinary retentionRenal and urinary disorders | 2/67 |
| LymphadenopathyBlood and lymphatic system disorders | 1/67 |
| Acute myocardial infarctionCardiac disorders | 1/67 |
| ArrhythmiaCardiac disorders | 1/67 |
| BradycardiaCardiac disorders | 1/67 |
| Cardiac arrestCardiac disorders | 1/67 |
| Event | Enzalutamide |
|---|---|
| GynaecomastiaReproductive system and breast disorders | 36/67 |
| FatigueGeneral disorders | 28/67 |
| HypertensionVascular disorders | 17/67 |
| Hot flushVascular disorders | 15/67 |
| Nipple painReproductive system and breast disorders | 13/67 |
| DiarrhoeaGastrointestinal disorders | 11/67 |
| NauseaGastrointestinal disorders | 11/67 |
| Back painMusculoskeletal and connective tissue disorders | 10/67 |
| ConstipationGastrointestinal disorders | 9/67 |
| Oedema peripheralGeneral disorders | 8/67 |
| Age, Continuous(Years) | Enzalutamide |
|---|---|
| Median | 73.0 (48 to 86) |
| Sex: Female, Male(Participants) | Enzalutamide |
|---|---|
| Female | 0 |
| Male | 67 |
| Body Mass Index (BMI)(kg/m²) | Enzalutamide |
|---|---|
| Median | 26.17 (20.8 to 39.7) |
| Prostate Specific Antigen (PSA)(ng/mL) | Enzalutamide |
|---|---|
| Median | 18.2 ± 102.990 |
| Duration of Prostate Cancer(years) | Enzalutamide |
|---|---|
| Median | 1.0 (0 to 16) |
| Total Gleason Score at Initial Diagnosis(Participants) | Enzalutamide |
|---|---|
| 4 | 1 |
| 5 | 5 |
| 6 | 10 |
| 7 | 34 |
| 8 | 7 |
| 9 | 6 |
| 10 | 3 |
| Unknown | 1 |
| Clinical Tumor Stage (T) at Initial Diagnosis(Participants) | Enzalutamide |
|---|---|
| TX: Primary tumor cannot be assessed | 1 |
| T0: No evidence of primary tumor | 1 |
| T1: Tumor neither palpable or visible by imaging | 9 |
| T2: Tumor confined within the prostate | 31 |
| T3: Tumor extends through the prostatic capsule | 18 |
| T4: Tumor is fixed or invades adjacent structures | 1 |
| Unknown | 6 |
| Clinical Lymph Node Stage (N) at Initial Diagnosis(Participants) | Enzalutamide |
|---|---|
| NX: Regional lymph nodes were not assessed | 24 |
| N0: No regional lymph node metastasis | 22 |
| N1: Metastasis in regional lymph node(s) | 6 |
| Unknown | 15 |
4 further baseline measures are reported on the registry.
Plan to share: Undecided
Ran from May 2011 to primary completion in Jul 2012, 14 months.
Results were first posted in Apr 2016, 3 years 8 months after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 14 months is below that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide